MedTrace Logo

Molecular Signatures of Cutaneous Dupilumab Response

NCT05858619 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-06-27

No results posted yet for this study

Summary

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Conditions

Interventions

DRUG

Dupilumab

dupilumab 600 mg injection initially and then 300 mg every other week

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Cheng, MD, PhD · University of California, San Francisco

  • Raymond Cho, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2026-02-01
Completion
2026-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858619 on ClinicalTrials.gov